101 College St. Rendering

100 College Street was the first of two towers slated for the developable land created by the Downtown Crossing Project. Currently, 100 College St (500,000 sq. ft.) is fully occupied by researchers from Alexion and Yale University.

Winstanley Enterprises has begun construction on the second bioscience tower at 101 College St. This is in response to the growing demand and to further connect the medical district and downtown area.

There are also other notable construction projects in the works, including 275 South Orange Street (planned construction in 2023, opening in 2025, and spanning 250,000 sq. ft.), Parcel B at Downtown Crossing (with an available site of 200-500,000 sq. ft.), and Science Park (with an available site of 200,000 sq. ft.).

The Greater New Haven area boasts esteemed bioscience research institutions, such as Yale University and Yale New Haven Health System. This region is a central hub for biotech and pharmaceutical companies that develop innovative treatments, particularly for rare diseases. While being situated between New York City and Boston facilitates collaboration, it also increases competition for both funding and skilled personnel. Therefore, it is vital to create more laboratory space for bioscience companies, especially those looking for graduate space without long-term leasing commitments.

Personalized medicine presents a significant growth opportunity for the region. The Yale Center for Genomic Health is tackling the most pressing challenge in the field: how to apply increasingly powerful genomic technologies and vast data resources to generate meaningful improvements in healthcare that will benefit people of all ancestry groups and ethnicities equitably.

Recent milestones:

• Alexion, AstraZeneca’s Rare Disease group, announced plans to expand in New Haven by leasing space at the bioscience tower under construction at 101 College Street.
• BioLabs manages incubator space at 101 College Street and Yale University’s West Haven campus.
• Additional laboratory spaces at Pierce Labs, 55 Church Street, and Winchester Works are meeting the emerging needs of many local biotech companies.
• Yale continues to spin out start-ups.
• Several biotechs are in a growth phase and continue adding employees.
• Conmed Corporation contracted to buy Biorez, underscoring the caliber of science being performed here.
• Ireland-based Nuritas is establishing its North American headquarters in New Haven, evidence of the growing appeal of the Elm City’s thriving bioscience ecosystem.
• New Haven has the country’s 20th-best life science workforce base, according to CBRE’s 2022 inaugural Life Sciences Talent Report.
• Life Science SPRINT (Student Program to Ready Interns for Next-generation Talent) created a pipeline into the Connecticut bioscience industry by pairing 170 students with paid internships with approximately 25 employers in the bioscience field.